Pharma Pioneer

PHV Launches First Marburg Vaccine Clinical Trial

19 May 2024
3 min read

A biotech firm from Cambridge, MA, known as Public Health Vaccines, has initiated a Phase 1 clinical trial for a novel vaccine candidate, PHV01, which targets the Marburg virus. This virus, a member of the Filoviridae family, is responsible for a severe hemorrhagic fever with a mortality rate that can reach 88%. It is listed as a high-priority pathogen by the WHO and is considered a potential threat for future pandemics, being classified as a Category A Select Agent.
The clinical trial, registered as NCT06265012, is designed to assess the safety and ability to provoke an immune response of the single-dose PHV01 vaccine. The study is structured as a randomized, single-blind, and placebo-controlled ascending-dose trial involving healthy U.S. adults. The vaccine employs a modified version of the rVSV platform, originally developed by the Public Health Agency of Canada, which has been used to create a one-dose vaccine against the Marburg virus. PHV01 is a live, attenuated vaccine that expresses the glycoprotein of the Marburg virus (Angola strain) and is expected to provide quick protection following a single administration, similar to the rVSV-EBOV vaccine used against Ebola.
Funding for the vaccine's development has been provided by the Biomedical Advanced Research and Development Authority (BARDA), which is part of the HHS's Administration for Strategic Preparedness and Response (ASPR). The contract number for this funding is HHSO100201900022C, and BARDA has the option to extend financial support up to $72 million, which would facilitate the completion of a Phase 2 trial and further steps towards regulatory approval.
Joan Fusco, COO of Public Health Vaccines, emphasized the urgency of developing vaccines in response to the recent Marburg outbreaks in Africa and other countries. The company is committed to creating PHV01 for both endemic use and global readiness. The ongoing clinical trial marks the first for a Marburg vaccine based on the rVSV platform and aims to replicate the success of the rVSV-EBOV vaccine. PHV expresses gratitude for BARDA's support and acknowledges the collective effort of its team and partners in reaching this significant milestone.
Public Health Vaccines, LLC, is a private biotech company based in Cambridge, MA, focused on developing products to combat emerging infectious diseases, including vaccines for the Marburg virus, Sudan ebolavirus, and Nipah virus. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Theratechnologies Advances to Higher Dosage in Sudocetaxel Zendusortide Phase 1 Ovarian Cancer Trial
Pharma Pioneer
2 min read
Theratechnologies Advances to Higher Dosage in Sudocetaxel Zendusortide Phase 1 Ovarian Cancer Trial
19 May 2024
Theratechnologies Inc., has progressed to a higher dosage level in the third phase of its clinical trial for a drug called sudocetaxel zendusortide.
Read →
Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
Pharma Pioneer
3 min read
Promising Preliminary Results for BLB201 RSV Vaccine in Pediatric Clinical Trial
19 May 2024
Blue Lake Biotechnology has released early findings from a Phase 1/2a clinical trial for BLB201.
Read →
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
Pharma Pioneer
3 min read
Andelyn and Grace Science Collaborate on AAV Gene Therapy Manufacturing for NGLY1 Deficiency
19 May 2024
Andelyn Biosciences has teamed up with Grace Science, LLC, to facilitate the technical transfer and production of GS-100, an AAV NGLY1 gene therapy for clinical trials.
Read →
Approval Granted to Brain Trust Bio for Phase I Trials of Novel IT Drug Delivery for ALS and CNS Conditions
Pharma Pioneer
2 min read
Approval Granted to Brain Trust Bio for Phase I Trials of Novel IT Drug Delivery for ALS and CNS Conditions
19 May 2024
Brain Trust Bio (BTB), a pioneering company in the field of central nervous system (CNS) disease treatment, has been granted the go-ahead to initiate Phase I clinical trials.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.